Abstract:Immune checkpoint inhibitors (ICIs), Ipilimumab, Nivolumab, Pembrolizumab and Atezolizumab, have been applied in anti-tumor therapy and demonstrated exciting performance compared to conventional treatments. However, the unsatisfactory response rates, high recurrence and adaptive resistance limit their benefits. Metabolic reprogramming appears to be one of the crucial barriers to immunotherapy. The deprivation of required nutrients and altered metabolites not only promote tumor progression but also confer dysfunction on immune cells in the tumor microenvironment (TME). Glycolysis plays a central role in metabolic reprogramming and immunoregulation in the TME, and many therapies targeting glycolysis have been developed, and their combinations with ICIs are in preclinical and clinical trials. Additional attention has been paid to the role of amino acids, lipids, nucleotides and mitochondrial biogenesis in metabolic reprogramming and clinical anti-tumor therapy. This review attempts to describe reprogramming metabolisms within tumor cells and immune cells, from the aspects of glycolysis, amino acid metabolism, lipid metabolism, nucleotide metabolism and mitochondrial biogenesis and their impact on immunity in the TME, as well as the significance of targeting metabolism in anti-tumor therapy, especially in combination with ICIs. In particular, we highlight the expression mechanism of programmed cell death (ligand) 1 [PD-(L)1] in tumor cells and immune cells under reprogramming metabolism, and discuss in detail the potential of targeting key metabolic pathways to break resistance and improve the efficacy of ICIs based on results from current preclinical and clinical trials. Besides, we draw out biomarkers of potential predictive value in ICIs treatment from a metabolic perspective.

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy

Metabolic Interventions Combined with CTLA-4 and PD-1/PD-L1 Blockade for the Treatment of Tumors: Mechanisms and Strategies.

Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment

Immunometabolism: a new dimension in immunotherapy resistance

Targeting metabolism to enhance immunotherapy within tumor microenvironment

Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment

Metabolic interventions: A new insight into the cancer immunotherapy

Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment

Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications

Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy

Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy

Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment

Metabolic Checkpoints and Novel Approaches for Immunotherapy Against Cancer

Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy

Metabolic Crosstalk in the Tumor Microenvironment Regulates Antitumor Immunosuppression and Immunotherapy Resisitance.

Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy

Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment